SUNPHARMA and DIVISLAB, both in Pharmaceuticals: Major. Monthly data through 2026-10-09. Change the comparison →
Share price change since Jan '19, the first month all 2 have a price: SUNPHARMA +316%, DIVISLAB +520%.
Rebased at 2019-01. Monthly closes from each company's history.
Months with a missing value are left as gaps.
The share price return over 3 years, split into net profit growth, share count change and the change in P/E.
SUNPHARMA: share price rose 62% over 3 years: +73 pts from net profit growth, −12 pts from the P/E change.
DIVISLAB: share price rose 176% over 3 years: +84 pts from net profit growth, +91 pts from the P/E change.
Segments are percentage points of the price return: price = P/E × net profit ÷ share count. These are the same numbers each company's own page shows.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | SUNPHARMA | DIVISLAB |
|---|---|---|
| Share Price | ₹1760.00 | ₹9340.00 |
| Market Cap | ₹4.22L cr | ₹2.48L cr |
| P/E | 141.0x | 84.3x |
| P/B | 18.9x | 14.8x |
| P/S | 20.2x | 22.5x |
| ROCE | 15.0% | 22.0% |
| ROE | 13.4% | 17.6% |
| Operating margin | 34.0% | 42.0% |
| Revenue (TTM), indexed to 100 | ₹20901 cr | ₹11005 cr |
| Net Profit (TTM) | ₹2993 cr | ₹2941 cr |
| Debt / Equity | 0.6x | 0.0x |
| Cash Conversion Cycle | 230d | 338d |
| Promoter holding | 54.5% | 51.9% |
| FII Holding | 14.5% | 20.2% |
| DII Holding | 22.1% | 19.3% |
| 12M momentum | 4.1% | 38.6% |
| Drawdown from Peak | -11.6% | -1.3% |
| Cash conversion (3Y) | 1.1x | 0.9x |
| Interest cover | 5.2x | 100.0x |
| Share Count Change (1Y) | 0.0% | 0.0% |
| Volatility (1Y) | 19.3% | 24.1% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.